Orally bioavailable potent soluble epoxide hydrolase inhibitors. - Wikidata - awgldk - TriplyDB

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

http://www.wikidata.org/entity/Q36999511

about

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor Synthesis and structure–activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism Mammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolase Soluble epoxide hydrolase inhibitors and heart failure Targeting epoxides for organ damage in hypertension Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation Soluble epoxide hydrolase inhibition modulates vascular remodeling Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches Multiphoton spectral analysis of benzo[a]pyrene uptake and metabolism in a rat liver cell line Vascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and ω-Hydroxylases EDHF function in the ductus arteriosus: evidence against involvement of epoxyeicosatrienoic acids and 12S-hydroxyeicosatetraenoic acid Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition.Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.Epoxyeicosatrienoic acid-dependent cerebral vasodilation evoked by metabotropic glutamate receptor activation in vivo.Soluble epoxide hydrolase inhibitor, t-TUCB, protects against myocardial ischaemic injury in rats.Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.Metabolomics reveals increased isoleukotoxin diol (12,13-DHOME) in human plasma after acute Intralipid infusion The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.Identification of potent inhibitors of the chicken soluble epoxide hydrolase.Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors.

P2860

Q24597172-20850487-0B58-4F13-AB00-DCC6B3306B5A Q24616753-2C7127E9-D7AD-4E24-9261-7E233E0D65F5 Q24625809-AEA04CB5-FF4F-40A0-8FE9-08035531801F Q27675485-50005949-E07B-4550-BE7E-4D2B27F5FDC5 Q27684895-9AA6EBF0-3B9C-4649-A2FF-B2E2B464C5C8 Q28245279-EF8FE343-6318-4E4E-A2A0-92FE5FC2C087 Q28302779-12A5A240-A6BF-4C52-AF8C-36E0A024FC6F Q28383423-2AB6FEA6-144F-4A78-8151-FFCF31791721 Q28387558-0FC329DF-60D5-47BA-87C9-9F55B270472A Q28387686-1D550A70-1716-4FB6-9FA3-0E87E814AD7B Q28388993-F0E4403B-8E88-4741-946F-7F3FC48C591F Q28389323-7ECC70FB-F807-4605-AEAA-6317C2712568 Q28391172-8C382D58-36E1-4AB5-9093-0AA8BE72C36A Q28391533-2B96531D-D72E-46B6-8989-1898F2963B24 Q28394250-2151A9C0-61E6-493E-A9E5-446617A6F2C8 Q28395856-42680515-2C9F-48C7-AF87-626ABCB10236 Q28396233-87DEA4B4-585A-43BF-8AE8-B3E2690CD931 Q28396881-CD38461E-F7AE-4B2F-A5ED-F0C9F3ED53E9 Q28396888-DCBFC5E3-785B-40C0-A112-3B218B8DF3B3 Q28397084-E9CE636D-B8FD-416F-B492-1E8509ED40FF Q28740769-2A0D077E-4B57-4CE3-B11A-B082C2D0D123 Q29248910-55246E61-EA71-47E1-931E-B3FCB6367B87 Q29347256-50492837-831C-4B4C-962F-19E436C7BDB0 Q33605509-876C4292-6AE7-45D3-B455-C1F7EF7BCDA1 Q33652488-E2086B34-D39B-4F85-9657-FBF65AF0B41F Q33665713-F27CF8CE-83B1-4FAE-8DDD-646E264F4BCF Q33717781-4226D0F3-DBD9-4363-862F-CBF5A1E1C8C2 Q33744236-B78153A3-A140-49CC-A065-655998595539 Q33814824-543111D9-1037-475C-8AEF-A1B544F1A34E Q33824233-AF698537-182D-49AA-9BA8-573F9E29492D Q33908066-F7228797-7965-415C-9CA2-DEAF108438B2 Q34052703-44B5AE9D-E19A-4792-AD88-63B5543B7DC0 Q34115301-9822F77F-B331-434D-8AF9-15CAA2589951 Q34231319-82180C24-8AF7-4EB6-BB9A-64D035DE9A58 Q34241120-A16B67AA-101A-40AA-8B29-B85E6EF5110A Q34282849-47E38D66-F96D-41FC-9CB0-C7C66C4A1FF5 Q34329204-EA9C80B4-CACC-4685-8572-AFDA610EB46D Q34347917-56436D47-2ED1-4CB3-B61B-BCAE724AE44B Q34778159-7D9008C3-12D8-4667-AB59-C41D4DC81126 Q34836888-1970CB26-49D5-4267-AEB6-9A762C748C59

P2860

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

http://www.wikidata.org/entity/Q36999511

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

@en

type

label

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

@en

prefLabel

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

@en

P1433

Q36999511-56B40017-679A-45A5-BFCA-61CF07845F7F

P1476

Q36999511-EBC68E7E-354A-47B2-8DE7-54F5F63EA61A

P2093

Q36999511-25D1E45C-81BF-4C7D-8EE9-B9B9F192D155

Q36999511-2D566A56-C6F3-4A8E-8E6C-A0C0AE990345

Q36999511-53448A4A-1552-4818-B0ED-8CE946B2DA09

Q36999511-A887E54B-33FD-4FAA-83DC-BAE57B37348B

Q36999511-B8484EE4-A2A0-4AF2-B324-0563DE0722CC

P2860

Q36999511-136B95D2-4F2F-4691-97EE-48C6E81EB9FF

Q36999511-155E640E-091B-4473-8C00-7121E6DFB9D0

Q36999511-165FCFBD-4B3B-4CA2-979A-BABB484F1947

Q36999511-1E6B15D1-4F70-4000-84D5-3FA0D10C3FF1

Q36999511-29D4A029-0E8E-449B-98D4-8B24B01FB5FD

Q36999511-2FCBBE0A-A08A-44D7-B086-10BAD9602338

Q36999511-30E9363E-DE49-4461-BF01-907F60831729

Q36999511-321A2B1D-6C02-4FA8-961F-56C45107ECD9

Q36999511-3D4191CB-F1E5-400D-88D8-DE1515C4217E

Q36999511-3FE649A5-1B92-40F7-9061-08F08D6856E4

P304

Q36999511-ACCF9192-C9DC-4784-84F0-BFB46D3C8ED5

P31

Q36999511-EC79AC1F-EE0B-4011-BF19-1E21EB8F7EE7

P356

Q36999511-BA89195D-0897-484B-8257-EDBAF41C88FE

P407

Q36999511-67603CBB-301E-4DF7-AFFD-EE4CF41F0B4A

P433

Q36999511-22DD9C63-4CE9-4936-ADD8-8F540604149E

P478

Q36999511-C7BEFFF7-25B1-4AC1-9079-2CC1EC0DB826

P577

Q36999511-40A20E48-1D2B-47DB-96D9-4CFD252E975B

P5875

Q36999511-743BCF25-3541-43E4-A786-212E2317281E

P698

Q36999511-D52D8CCB-D592-4062-84F9-177A41310030

P932

Q36999511-9B71F183-F87D-47B3-A494-3D56ACCA002E

P356

P1433

Journal of Medicinal Chemistry

P1476

Orally bioavailable potent soluble epoxide hydrolase inhibitors.

@en

P2093

Bruce D Hammock

http://www.w3.org/2001/XMLSchema#string

Christophe Morisseau

http://www.w3.org/2001/XMLSchema#string

Hsing-Ju Tsai

http://www.w3.org/2001/XMLSchema#string

Jun-Yan Liu

http://www.w3.org/2001/XMLSchema#string

Sung Hee Hwang

http://www.w3.org/2001/XMLSchema#string

P2860

Epoxide hydrolases: biochemistry and molecular biology

cDNA cloning and expression of a soluble epoxide hydrolase from human liver

Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase

Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function

Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles

Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

Differential induction of hepatic drug-metabolizing enzymes by fenvaleric acid in male rats

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension

Soluble epoxide hydrolase is a therapeutic target for acute inflammation

P304

3825-3840

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM070270T

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6222015

http://www.w3.org/2001/XMLSchema#string

P698

17616115

http://www.w3.org/2001/XMLSchema#string

P932

2596069

http://www.w3.org/2001/XMLSchema#string